We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

160 hedge funds and large institutions have $1.5B invested in Epizyme, Inc in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 67 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,585% more call options, than puts

Call options by funds: $59.2M | Put options by funds: $3.52M

86% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 36

86% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 21

12% more funds holding

Funds holding: 143160 (+17)

11% more funds holding in top 10

Funds holding in top 10: 910 (+1)

2% more capital invested

Capital invested by funds: $1.47B → $1.5B (+$29.2M)

Holders
160
Holders Change
+17
Holders Change %
+11.89%
% of All Funds
3.28%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.21%
New
39
Increased
67
Reduced
36
Closed
21
Calls
$59.2M
Puts
$3.52M
Net Calls
+$55.7M
Net Calls Change
+$12.7M
Name Holding Trade Value Shares
Change
Change in
Stake
Swiss National Bank
51
Swiss National Bank
Switzerland
$2.53M +$281K +16,100 +11%
State of Wisconsin Investment Board
52
State of Wisconsin Investment Board
Wisconsin
$2.29M +$398K +22,800 +19%
AllianceBernstein
53
AllianceBernstein
Tennessee
$2.25M +$593K +34,000 +32%
AA
54
ALPS Advisors
Colorado
$2.21M -$484K -27,719 -17%
Citadel Advisors
55
Citadel Advisors
Florida
$2.04M +$1.51M +86,422 +211%
AI
56
Atom Investors
Texas
$1.97M -$2.2M -126,108 -51%
Citigroup
57
Citigroup
New York
$1.87M +$1.13M +64,764 +125%
AQR Capital Management
58
AQR Capital Management
Connecticut
$1.83M -$146K -8,353 -7%
Point72 Asset Management
59
Point72 Asset Management
Connecticut
$1.79M +$1.95M +111,620 New
State of New Jersey Common Pension Fund D
60
State of New Jersey Common Pension Fund D
New Jersey
$1.7M -$667K -38,205 -27%
NSIM
61
North Star Investment Management
Illinois
$1.58M +$717K +41,100 +71%
MSL
62
Mackay Shields LLC
New York
$1.35M +$459K +26,300 +46%
New York State Common Retirement Fund
63
New York State Common Retirement Fund
New York
$1.31M +$209K +12,000 +17%
Russell Investments Group
64
Russell Investments Group
United Kingdom
$1.28M -$2.11K -121 -0.2%
EAM
65
Erste Asset Management
Austria
$1.22M
Marshall Wace
66
Marshall Wace
United Kingdom
$1.2M +$631K +36,158 +95%
Two Sigma Advisers
67
Two Sigma Advisers
New York
$1.17M +$1.28M +73,100 New
Squarepoint
68
Squarepoint
New York
$1.16M +$1M +57,348 +390%
BC
69
Birchview Capital
Vermont
$1.12M +$175K +10,000 +17%
UBS AM
70
UBS AM
Illinois
$1.11M +$81.1K +4,644 +7%
MWNA
71
Marshall Wace North America
New York
$1.11M +$506K +29,016 +73%
Barclays
72
Barclays
United Kingdom
$1.1M +$581K +33,266 +93%
Wells Fargo
73
Wells Fargo
California
$997K +$348K +19,928 +47%
CAM
74
ClariVest Asset Management
California
$922K -$23.4K -1,340 -2%
ASP
75
Adams Street Partners
Illinois
$912K +$991K +56,780 New

EPZM Hedge Fund Activity: Q2 2020 in Review

160 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2020, worth a combined $1.5B — up 2% from $1.47B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new EPZM positions and 21 closed out — a net gain of 18 holders — while 67 added to existing stakes and 36 trimmed.

The largest buyer was Primecap Management, adding an estimated $26M. The largest seller was NEA Management Company, exiting entirely with an estimated $67.9M sold.

  • 160 institutional investors held Epizyme, Inc (EPZM) as of Q2 2020, up from 143 in Q1 2020.
  • Funds reported $1.5B of Epizyme, Inc stock for Q2 2020, up 2% quarter-over-quarter.
  • 39 funds opened new Epizyme, Inc positions in Q2 2020 and 21 closed out, a net change of +18 holders.
  • The largest Epizyme, Inc buyer in Q2 2020 was Primecap Management, an estimated $26M added.
  • The largest Epizyme, Inc seller in Q2 2020 was NEA Management Company, an estimated $67.9M sold.

Based on aggregated 13F filings for Q2 2020.